Beta-lactamase inhibitor-protected cephalosporins

Mechanism of action and role of sulbactam

The creation of inhibitor-protected cephalosporins is based on the need to overcome bacterial resistance. The primary weapon of many pathogenic microorganisms against antibiotics is the production of specific enzymes — $\beta$-lactamases. These enzymes hydrolyze the antibiotic molecule, destroying its structure and completely depriving the drug of antibacterial activity.

To solve this problem, a special component is introduced into the drug composition. Let us consider this mechanism using the well-known combination of cefoperazone/sulbactam (Sulperazon). In this tandem, sulbactam acts as a $\beta$-lactamase inhibitor. Its main role is to take the enzymatic blow upon itself: it binds to bacterial $\beta$-lactamases and blocks their activity. This prevents the hydrolysis of cefoperazone itself. The base antibiotic remains in its active form, unimpededly reaches targets on the surface of the microbial cell, and exerts its pronounced effect. Thus, the inhibitor acts as a reliable pharmacological shield.

Transformation of the antimicrobial spectrum

The addition of a $\beta$-lactamase inhibitor not only protects the antibiotic but also fundamentally changes its clinical capabilities. The spectrum of action of a protected cephalosporin is significantly expanded compared to its unprotected precursor.

According to pharmacological data, this expansion occurs due to two major groups of microorganisms:

1. Anaerobic flora. The drug acquires high activity against bacteria capable of multiplying in an oxygen-free environment. This is a critically important property for treating deep purulent foci.
2. Enterobacteriaceae producing $\beta$-lactamases. Many strains of the enteric group of bacteria have the ability to produce destructive enzymes. The combination with sulbactam makes these resistant strains sensitive to therapy once again.

As a result of this dual spectrum expansion, the drug becomes a powerful tool for combating infections caused by multidrug-resistant and mixed (aerobic-anaerobic) flora. Mixed microorganism associations pose the greatest challenge in clinical practice, as they require the use of drugs with the broadest possible coverage of causative agents.

Clinical indications and localization of infections

Given its powerful antibacterial potential, inhibitor-protected cephalosporins are positioned as drugs for the treatment of severe nosocomial (hospital-acquired) infections. Hospital flora traditionally exhibits a high degree of resistance to standard antibiotics, thus requiring the use of protected combinations.

The drug cefoperazone/sulbactam is indicated for severe infections of various body systems:

• Lower respiratory tract: the drug is effective in treating severe pneumonia, as well as destructive processes such as lung abscess and empyema thoracis (accumulation of pus in the pleural cavity).
• Abdominal cavity and pelvic organs: infections of the gastrointestinal tract and pelvic organs, where mixed aerobic-anaerobic flora historically predominates.
• Urinary tract: therapy for complicated infections unresponsive to first-line drugs.
• Systemic infections: comprehensive treatment of sepsis when the pathogen circulates in the blood and threatens the patient's life.

Use in special patient groups

The use of inhibitor-protected cephalosporins in patients with critically depleted immune reserves warrants special attention.

In clinical practice, the drug is actively used to treat infectious complications against the background of neutropenia (marked decrease in blood neutrophil count) and general immunodeficiency. In such patients, the body is unable to contain bacterial aggression on its own. Under these conditions, it is necessary to prescribe an antibiotic that not only has a broad spectrum of activity against multidrug-resistant flora, but is also guaranteed not to be destroyed by bacterial enzymes at the site of infection. The protected combination of cefoperazone and sulbactam fully meets these strict requirements, ensuring reliable eradication of the pathogen even in the absence of an adequate immune response.

Briefly: answers to topical questions

Class and exam questions

What else to study on this topic

• Mechanism of enzymatic hydrolysis of antibiotics by β-lactamases.
• Characteristics of multidrug-resistant hospital-acquired (nosocomial) flora.
• The role of anaerobes in the development of abscesses and pleural empyema.
• Specifics of antibacterial therapy against the background of pronounced neutropenia and immunodeficiency.
• Principles of treatment of mixed aerobic-anaerobic pelvic and GI infections.

Other topics in the section "Antibacterial Chemotherapeutic Agents"

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.